Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

November 20, 2023

Please see attachment.

Contact information

Investor RelationsAnders Mohr Christensen+45 2515 2364dkamc@chr-hansen.com

Press RelationsSanne Seyer-Hansen+45 6038 6207dksash@chr-hansen.com

Attachment

  • 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen
Grafico Azioni Chr Hansen (TG:51C)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Chr Hansen
Grafico Azioni Chr Hansen (TG:51C)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Chr Hansen